Why the study?
IL-6 is an emerging therapeutic target in MI with proinflammatory trans-signaling and anti-inflammatory classic signaling pathways, but whether selective trans-signaling blockade differs from panantagonism is unclear.
Does sgp130Fc reduce infarct size and preserve cardiac function compared to anti-IL-6 antibodies in a rat model of reperfused MI?
Does sgp130Fc reduce infarct size and preserve cardiac function compared to anti-IL-6 antibodies in a rat model of reperfused MI?
Selective IL-6 trans-signaling blockade with sgp130Fc reduces infarct size and preserves cardiac function in a rat model of reperfused MI, outperforming panantagonism with anti-IL-6 antibodies.
Answers are grounded in this paper and cite their sources.
Selective IL-6 trans-signaling blockade attenuates post-MI infiltration in rats unlike panantagonism; leaves open human translation.
Interleukin (IL)-6 is an emerging therapeutic target in myocardial infarction (MI). IL-6 has 2 distinct signaling pathways: trans-signaling, which mediates inflammation, and classic signaling, which also has anti-inflammatory effects. The novel recombinant fusion protein sgp130Fc achieves exclusive trans-signaling blockade, whereas anti-IL-6 antibodies (Abs) result in panantagonism. In a rat model of reperfused MI, sgp130Fc, but not anti-IL-6-Ab, attenuated neutrophil and macrophage infiltration into the myocardium, reduced infarct size, and preserved cardiac function 28 days after MI. These data demonstrate the efficacy of exclusive IL-6 trans-signaling blockade and support further investigation of sgp130Fc as a potential novel therapy in MI.
No takes yet. Share an insight, caveat, or question.
George et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: